Xoma reported $120.79M in Debt for its fiscal quarter ending in June of 2024.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Agenus USD 35.54M 2.34M Mar/2025
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
Ardelyx USD 207.61M 968K Sep/2025
aTyr Pharma USD 1.84M 8K Sep/2025
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Celldex Therapeutics USD 2.34M 285K Dec/2025
Curis USD 0 0 Jun/2022
Eli Lilly USD 42.5B 3.6M Dec/2025
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
Incyte USD 39.43M 982K Mar/2026
MacroGenics USD 37.01M 238K Sep/2025
Novartis USD 47B 11.62B Mar/2026
Novartis USD 32.02B 615M Sep/2025
Pfizer USD 63.73B 231M Mar/2026
Prothena USD 9.08M 699K Sep/2025
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Xoma USD 120.79M 3.27M Jun/2024